Protagonist Therapeutics (PTGX) Gains from Sales and Divestitures (2019 - 2025)
Historic Gains from Sales and Divestitures for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $75500.0.
- Protagonist Therapeutics' Gains from Sales and Divestitures changed N/A to $75500.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $75500.0, marking a year-over-year change of. This contributed to the annual value of $316748.0 for FY2024, which is 468.17% up from last year.
- According to the latest figures from Q3 2025, Protagonist Therapeutics' Gains from Sales and Divestitures is $75500.0.
- In the past 5 years, Protagonist Therapeutics' Gains from Sales and Divestitures registered a high of $316748.0 during Q4 2024, and its lowest value of $75500.0 during Q3 2025.
- Over the past 5 years, Protagonist Therapeutics' median Gains from Sales and Divestitures value was $104712.0 (recorded in 2022), while the average stood at $147548.4.
- In the last 5 years, Protagonist Therapeutics' Gains from Sales and Divestitures plummeted by 4039.89% in 2021 and then soared by 17152.67% in 2023.
- Quarter analysis of 5 years shows Protagonist Therapeutics' Gains from Sales and Divestitures stood at $78165.0 in 2021, then skyrocketed by 38.76% to $108462.0 in 2022, then surged by 178.98% to $302582.0 in 2023, then increased by 4.68% to $316748.0 in 2024, then plummeted by 76.16% to $75500.0 in 2025.
- Its Gains from Sales and Divestitures stands at $75500.0 for Q3 2025, versus $316748.0 for Q4 2024 and $302582.0 for Q4 2023.